Potential 'significance' of monoclonal gammopathy of 'undetermined significance' during COVID-19 pandemic

Affiliations

¹ Department of Haematology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. Electronic address: drankur589@yahoo.in.
² Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, United Kingdom of Great Britain and Northern Ireland; NIHR BRC Blood Theme, Oxford, United Kingdom of Great Britain and Northern Ireland; Oxford Myeloma Centre for Translational Research, United Kingdom of Great Britain and Northern Ireland.

Ankur Jain et al. Blood Cells Mol Dis. 2020 Nov.

. 2020 Nov:85:102481.

doi: 10.1016/j.bcmd.2020.102481. Epub 2020 Jul 24.

¹ Department of Haematology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. Electronic address: drankur589@yahoo.in.
² Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, United Kingdom of Great Britain and Northern Ireland; NIHR BRC Blood Theme, Oxford, United Kingdom of Great Britain and Northern Ireland; Oxford Myeloma Centre for Translational Research, United Kingdom of Great Britain and Northern Ireland.

No abstract available

References

1. Wadhera R.K., Rajkumar S.V. Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin. Proc. 2010;85:933–942. - PMC - PubMed
1. van de Donk N.W., Palumbo A., Johnsen H.E. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European myeloma network. Haematologica. 2014;99:984–996. - PMC - PubMed
1. Fermand J.P., Bridoux F., Dispenzieri A. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132:1478–1485. - PubMed
1. Tete S.M., Bijl M., Sahota S.S., Bos N.A. Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. Front. Immunol. 2014;5:25. doi: 10.3389/fimmu.2014.00257. - DOI - PMC - PubMed
1. Onder G., Rezza G., Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020 doi: 10.1001/jama.2020.4683. - DOI - PubMed